4.5 Article

Irreversible Primary Visual Cortex Impairment in a Mouse Model of High-Risk Schizophrenia

期刊

NEUROPSYCHIATRIC DISEASE AND TREATMENT
卷 2021, 期 -, 页码 277-282

出版社

DOVE MEDICAL PRESS LTD
DOI: 10.2147/NDT.S246163

关键词

schizophrenia; animal model; primary visual cortex; antipsychotics

资金

  1. National Natural Science Foundation of China [81871052, 81801679, 81571319]
  2. Key Projects of the Natural Science Foundation of Tianjin, China [17JCZDJC35700]
  3. Tianjin Health Bureau Foundation [2014KR02]
  4. National Key Research and Development Program of China [2016YFC1307004]
  5. Shanxi Science and Technology Innovation Training Team's Multidisciplinary Team for Cognitive Impairment [201705D131027]
  6. Zhejiang Public Welfare Fund Project [LGF18H090002]
  7. Wenzhou Science and Technology Bureau [ZS2017011]
  8. Tianjin 131 Scholar Project
  9. Tianjin Anding Hospital of 300000 Scholar Award Project

向作者/读者索取更多资源

This study focused on investigating the pathological changes of the primary visual cortex in a prenatal mouse model of MK801-induced high-risk schizophrenia. The results showed that both groups of HRMMS mice, with or without antipsychotic treatment, had decreased neuronal calcium activity in the primary visual cortex, which was not improved by the treatment. This suggests the presence of independent regulatory pathways for visual perception disturbance in schizophrenia.
Purpose: Although visual deficits can be observed at any stage of schizophrenia, few studies have focused on visual cortex alterations in individuals at high risk of schizophrenia. This study aimed to investigate the pathological changes of the primary visual cortex in a prenatal mouse model of MK801-induced high-risk schizophrenia. Methods: The high-risk schizophrenia model was generated by MK801 injection into pregnant mice. The male offspring without schizophrenia-like behaviors in early adulthood were defined as the high-risk mouse model of schizophrenia (HRMMS) and divided into two groups. One HRMMS group received the antipsychotic agent risperidone beginning at postnatal week 4 and another group did not receive any treatment. After treatment for 4 weeks, in vivo two-photon calcium imaging was performed to characterize the primary visual cortex activity. The novel object recognition test and the prepulse inhibition apparatus test were also implemented to assess the cognitive and behavioral performance, respectively. Results: Both groups of HRMMS mice, with or without antipsychotic treatment, had decreased neuronal calcium activity, demonstrating primary visual cortex impairment. More notably, antipsychotic treatment did not normalize the impaired neuronal activities in the primary visual cortex. Correspondingly, the treatment did not improve the cognitive or behavioral impairment. Conclusion: Visual cortex impairment might be a prominent feature of individuals at high risk of schizophrenia that cannot be normalized by early treatment with antipsychotic medication, indicating the presence of independent regulatory pathways for visual perception disturbance in schizophrenia. Thus, visual system impairment in schizophrenic patients must be further studied.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据